ConductScience.org, home

Paper14990649

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

Yeo W and 11 others. J Clin Oncol, 2004. Cited by 211 papers, by iCite.

Cite this record

ConductScience Library. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. Papers, record 14990649. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14990649

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
PubMed
Journal
J Clin Oncol
PubMed
Year
2004
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Comparative Study, Controlled Clinical Trial, Journal Article
PubMed
Citations, by iCite
211
iCite
Relative citation ratio, by iCite
5.29
iCite
Revised in PubMed
2022-03-18
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yeo WWinnie
2Chan PKPaul K S
3Ho WMWing M
4Zee BBenny
5Lam KCKwok C
6Lei KIKenny I K
7Chan ATAnthony T C
8Mok TSTony S K
9Lee JJJam J
10Leung TWThomas W T
11Zhong SSheng
12Johnson PJPhilip J

Source PubMed

Download CSV of authors

Topics27

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis BMajor topic
Hepatitis B Surface AntigensMajor topic
Hepatitis B virusMajor topic
LamivudineMajor topic
NeoplasmsMajor topic
Adult
Age Distribution
Aged
Carrier State
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Incidence
Male
Middle Aged
Neoplasm Staging
Primary Prevention
Probability
Prognosis
Reference Values
Risk Assessment
Secondary Prevention
Serologic Tests
Sex Distribution
Survival Analysis
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by78

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.

PMIDTitleJournalYearIn PapersSource
38958900Cross-sectional study of hepatitis B virus infection in female breast cancer patients in China for the first time diagnosed.Clin Transl Oncol2025https://conductscience.org/library/papers/38958900PubMed
37731995Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.World J Gastroenterol2023https://conductscience.org/library/papers/37731995PubMed
37463687Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study.J Korean Med Sci2023https://conductscience.org/library/papers/37463687PubMed
36072805Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era.Front Oncol2022https://conductscience.org/library/papers/36072805PubMed
35478052Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation.J Gastroenterol2022https://conductscience.org/library/papers/35478052PubMed
35430783KASL clinical practice guidelines for management of chronic hepatitis B.Clin Mol Hepatol2022https://conductscience.org/library/papers/35430783PubMed
34427860APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.Hepatol Int2021https://conductscience.org/library/papers/34427860PubMed
33576088Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.Cancer Sci2021https://conductscience.org/library/papers/33576088PubMed
32729014Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.Dig Dis Sci2021https://conductscience.org/library/papers/32729014PubMed
32013312Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases.Intest Res2020https://conductscience.org/library/papers/32013312PubMed
31752356Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.Cancers (Basel)2019https://conductscience.org/library/papers/31752356PubMed
31540124Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management.Viruses2019https://conductscience.org/library/papers/31540124PubMed
31526114Analysis of Hepatitis B Virus Reactivation After Radiotherapy in Patients With Hepatocellular Carcinoma Using the Lyman NTCP Model.Technol Cancer Res Treat2019https://conductscience.org/library/papers/31526114PubMed
31290069Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers.Hepatol Int2019https://conductscience.org/library/papers/31290069PubMed
31185710KASL clinical practice guidelines for management of chronic hepatitis B.Clin Mol Hepatol2019https://conductscience.org/library/papers/31185710PubMed
31040945Defining and grading HBV reactivation.Clin Liver Dis (Hoboken)2015https://conductscience.org/library/papers/31040945PubMed
29977329Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma.Infect Agent Cancer2018https://conductscience.org/library/papers/29977329PubMed
29606020Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma.Cancer Control2018https://conductscience.org/library/papers/29606020PubMed
28717701Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.J Glob Oncol2016https://conductscience.org/library/papers/28717701PubMed
28219691Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Gastroenterology2017https://conductscience.org/library/papers/28219691PubMed

See all 78 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/14990649

GET https://conductscience.org/api/papers/v1/14990649/cited_by?page=2